Skip to main content
Barinthus Biotherapeutics plc. logo

Barinthus Biotherapeutics plc. - Investor Relations & Filings

Listed IPO Jul 2021
Ticker · BRNS ISIN · US91864C1071 LEI · 213800KQ9EAOKPWN8A33 US Manufacturing
Open in API
Filings indexed 243 across all filing types
Latest filing 2026-07-02 Declaration of Voting R…
Country GB United Kingdom
Listing US BRNS · 7 venues

Key figures FY2024

Period ended 2024-12-31 · USD
Headline annual figures for Barinthus Biotherapeutics plc., fiscal year 2024, reported in USD, with the source filing for each figure.
Total Revenues USD 14.97M per the Annual Report filed 2025-03-20
Net Income USD -61.18M per the Annual Report filed 2025-03-20
Total Assets USD 160.33M per the Annual Report filed 2025-03-20
Total Equity USD 130.13M per the Annual Report filed 2025-03-20
Cash from Ops USD -28.94M per the Annual Report filed 2025-03-20

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Barinthus Biotherapeutics plc.

https://www.barinthusbio.com/

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company that develops novel immunotherapies designed to guide T cells to control disease. The company is advancing a new generation of antigen-specific immunotherapeutics for treating autoimmunity, chronic infectious diseases, and cancer. Its therapeutic approach focuses on creating candidates that can overcome these conditions by modulating the body's T cell response. The development pipeline includes programs targeting various indications, with a strategic focus on immunology and inflammatory diseases.

Recent filings

Filing Released Lang Actions
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC by Barinthus Biotherapeutics plc. It includes detailed official voting results from the company's 2026 Annual General Meeting, such as election of directors and approval of auditors. It also discusses a Nasdaq compliance notification and extension related to the company’s stock listing. The presence of official vote results from the AGM explicitly matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is adequate (8728 characters) for a full report, not a brief announcement, and contains substantive meeting content, further confirming it is not simply a Notice or Regulatory Filing. Therefore, the appropriate classification is DVA.
2026-07-02 English
ARS
Annual Report FY 2025
2026-06-10 English
DEF 14A
Proxy Solicitation & Information Statement
2026-06-10 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K “Current Report” filed under Exchange Act Section 13/15(d) describing Item 5.07 “Submission of Matters to a Vote of Security Holders,” including the final vote tallies and results at a Court Meeting and General Meeting. This clearly constitutes an official declaration of voting results at shareholder meetings. Therefore, it falls under Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-21 English
10-Q - Barinthus Biotherapeutics plc. (0001828185) (Filer)
Interim / Quarterly Report Q1 2026
2026-04-30 English
8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text includes an Item 2.02 section titled 'Results of Operations and Financial Condition' and mentions a press release with financial results for the quarter ended March 31, 2026. The document also references a registration statement on Form S-4 related to a proposed transaction, indicating merger-related activity. However, the primary content is the announcement of quarterly financial results via a press release attached as Exhibit 99.1. The document is not the full quarterly report itself but a current report announcing financial results. Therefore, it fits best under the category of Earnings Release (ER), which covers initial announcements of quarterly financial results. The document length (7049 characters) supports it being more than a brief notice but still an announcement rather than a full interim report. Hence, the classification is ER with high confidence. Q1 2026
2026-04-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.